8-K: DURECT Corp Announces Positive Q2 Results and Breakthrough Therapy Designation for Larsucosterol

DURECT Corporation reported its second quarter 2024 financial results, highlighted by a Breakthrough Therapy Designation from the FDA for its drug candidate, larsucosterol, in treating alcohol-associated hepatitis.

Summary

• DURECT Corporation announced its second quarter 2024 financial results, showing a net loss of $3.7 million compared to a net loss of $11.2 million for the same period in 2023.
• Total revenues for the quarter were $2.2 million, slightly up from $2.1 million in the second quarter of 2023.
• The company's cash, cash equivalents, and investments totaled $15.8 million as of June 30, 2024, down from $29.8 million at the end of 2023.
• Debt decreased to $12.5 million at the end of the second quarter, compared to $16.7 million at the end of 2023.
• The FDA granted Breakthrough Therapy Designation to larsucosterol for the treatment of alcohol-associated hepatitis, which is intended to expedite the development and review of promising therapies.
• DURECT held a Type B meeting with the FDA to discuss the design of its planned Phase 3 clinical trial for larsucosterol.
• The company plans to initiate the Phase 3 trial by the end of 2024, with topline results expected in the second half of 2026, subject to obtaining sufficient funding.
• Data from the Phase 2b AHFIRM trial were presented at the European Association for the Study of the Liver (EASL) Congress in June 2024.

Sentiment

Score: 7

Explanation: The document has a positive tone due to the Breakthrough Therapy Designation and improved financial results, but there are risks associated with funding and clinical trial outcomes.

Positives

• The FDA granted Breakthrough Therapy Designation to larsucosterol, which could accelerate its development and approval.
• The company had a productive meeting with the FDA regarding the Phase 3 trial design.
• The net loss significantly decreased year-over-year, indicating improved financial performance.
• The company's debt decreased from the end of 2023.
• The company presented data from the Phase 2b AHFIRM trial at a major medical conference.

Negatives

• The company's cash reserves decreased significantly from the end of 2023.
• The company is still operating at a loss.
• The initiation of the Phase 3 trial is contingent on securing sufficient funding.

Risks

• The company may not be able to raise sufficient capital to commence the Phase 3 trial.
• Clinical trials may take longer than anticipated or not confirm previous results.
• The FDA may require additional clinical trials before approving larsucosterol.
• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company needs to maintain a minimum bid price to remain listed on the Nasdaq.

Future Outlook

DURECT plans to initiate a Phase 3 trial for larsucosterol by the end of 2024, with topline results expected in the second half of 2026, contingent on securing sufficient funding. The company is also exploring larsucosterol for other indications such as MASH.

Management Comments

• Our immediate priority is to finalize the design of our planned pivotal Phase 3 trial of larsucosterol in alcohol-associated hepatitis, stated James E. Brown, D.V.M., President and CEO of DURECT.
• We are encouraged by the FDAs feedback on our plans to advance development of larsucosterol, including its granting of Breakthrough Therapy Designation, and look forward to providing a further update on specifics of the Phase 3 design following expected communications from FDA.
• We are committed to advancing development of larsucosterol and bringing this potentially lifesaving therapy to patients as quickly as possible.

Industry Context

The announcement is significant as there are currently no FDA-approved therapies for alcohol-associated hepatitis, and larsucosterol has the potential to be the first. The Breakthrough Therapy Designation highlights the unmet medical need and the potential of larsucosterol to address it. The company is also exploring the drug for other indications such as MASH, which is a growing area of interest in the pharmaceutical industry.

Comparison to Industry Standards

• The mortality rates for alcohol-associated hepatitis are high, with a 28-day mortality rate of 26% in a retrospective analysis and approximately 20% in a more recent global study, highlighting the urgent need for effective treatments.
• Current treatments, such as corticosteroids, have limitations and have not shown to improve survival at 90 days or one year.
• Liver transplantation is an option but is limited by organ availability and high costs, with average charges exceeding $875,000.
• DURECT's larsucosterol, with its epigenetic mechanism of action, represents a novel approach compared to existing therapies, potentially offering a more effective treatment option.

Stakeholder Impact

• Shareholders may see increased value if larsucosterol is successful in Phase 3 and gains FDA approval.
• Employees may benefit from the company's progress and potential growth.
• Patients with alcohol-associated hepatitis could have a new treatment option if larsucosterol is approved.
• Creditors may be more confident in the company's ability to repay debt due to improved financial performance.

Next Steps

• Finalize the design of the Phase 3 clinical trial for larsucosterol.
• Obtain sufficient funding to initiate the Phase 3 trial.
• Initiate the Phase 3 trial by the end of 2024.
• Provide further updates on the Phase 3 trial design following communications from the FDA.
• Report topline results from the Phase 3 trial in the second half of 2026.

Key Dates

Keywords

larsucosterol, alcohol-associated hepatitis, FDA, Breakthrough Therapy Designation, Phase 3 trial, clinical trial, AHFIRM trial, epigenetic therapy, financial results, DURECT